🔴 Live Zoom Event  |  August 14, 2025, 6PM CT

BTK Inhibitors and Beyond: The Next Wave of MS Innovation

Get straight answers about the BTK inhibitors in development, more MS research updates, and what they could mean for your MS care. No medical jargon, no false promises - just facts from research experts.

 Hosted by: 

473667690_622929316775723_4811524761778533102_n

     When: Thursday, August 14, 2025 at 6:00 PM CT

    Where: Zoom. Join from anywhere. 

Button not working? Try these:

Link: https://us02web.zoom.us/j/5907102196?pwd=R0Q3Wmx0b1BZci96aWlwUG1IZlp0QT09
Zoom Meeting ID: 590 710 2196

Get Reminders & Follow-Up Materials

00
Days
00
Hours
00
Minutes
00
Seconds
BTK Event

Joined our July BTK Inhibitor discussion? Ready to go deeper.
Missed it? This is your chance to get the complete picture.

This session goes beyond the BTK inhibitor headlines with Wayne Pickerell, a Clinical Research Manager conducting these studies at SC3 Research Group.

Get detailed answers about the 4 BTK inhibitors in development, real clinical trial results, and practical guidance about what these treatments actually mean for people living with MS.

Direct access to a researcher who evaluates patients for these studies daily - ask the questions that matter most to you.
GET REMINDERS & RECORDING

What You'll Learn

🔬 The Complete BTK Inhibitor Landscape

4 different approaches to BTK inhibition and why they matter

Real clinical trial results - both successes and setbacks

Progressive MS breakthrough potential - addressing the greatest unmet need

Safety considerations and monitoring requirements

🧠 Beyond BTK: The Next Generation

Patient selection criteria - who benefits most from new approaches

Research participation - accessing cutting-edge treatments

Treatment sequencing - optimizing your MS care strategy

Pipeline innovations - what's coming in 2026-2027

Why This Matters Now

Gemini_Generated_Image_rz8cjurz8cjurz8c-2
BTK inhibitors represent a promising advancement in MS treatment, particularly for progressive forms of the disease that have been challenging to treat. Multiple pharmaceutical companies are developing BTK inhibitors in late-stage trials1, with the first potential FDA approval decision expected by September 20252.
 
What makes BTK inhibitors particularly significant is their potential to help people with MS3 - a population that has had limited treatment options until now. For the first time, researchers are seeing evidence that a treatment can slow disability progression independent of relapses4, which could be meaningful for people experiencing gradual worsening of symptoms5 like walking difficulties, cognitive changes, or fatigue6. Whether you're currently managing progressive MS or want to understand what options might be available in the future, this session will help you navigate the evolving treatment landscape.


References: 
  1. Sanofi Press Release: Tolebrutinib regulatory submission accepted for priority review, March 25, 2025
  2. Clinical Trials Arena: BTK inhibitor development landscape analysis, April 9, 2025
  3. AJMC: Tolebrutinib delays disability progression in nonrelapsing secondary progressive MS, September 3, 2024
  4. Cleveland Clinic ConsultQD: Disability progression slowed for first time in nonrelapsing secondary progressive multiple sclerosis, April 9, 2025
  5. Mayo Clinic: Multiple sclerosis symptoms and causes, November 1, 2024
  6. National Institute of Neurological Disorders: Multiple sclerosis overview, January 31, 2025

More About the MS Event

Zoom meeting

This is a monthly series

This BTK inhibitor session kicks off our monthly "MS Research Roundup" series - a collaboration between Modified by MS and SC3 Research Group. Each month, we'll tackle a different research topic that matters to the MS community.

473667690_622929316775723_4811524761778533102_n

Hosted by Modified by MS

Modified by MS connects and encourages MS warriors while providing resources to help them live their best life. Our mission: "NOT BROKEN. NOT DEFEATED. JUST MODIFIED."

SC3 Logo

Our Research Partner

SC3 Research Group conducts clinical research in neurological conditions including MS, Parkinson's, and Alzheimer's. Based in Pasadena, California, they're committed to making cutting-edge research accessible to local communities.

MS Research Roundup: Live Zoom Discussion

A free, open conversation for the MS community — drop in any time to hear from experts and MS Warriors about the latest in MS research.
Wednesday, August 14, 2025 · 6:00 PM CT

00
Days
00
Hours
00
Minutes
00
Seconds
Join the Discussion – No Registration Needed

Frequently Asked Questions

Do I need to register to attend?

No! You can join the Zoom event directly without providing any information. The optional form is only if you want reminders before the event and access to the recording and key takeaways afterward.

You'll need a computer, tablet, or smartphone with internet
  • •Zoom app (free) or web browser
  • Microphone if you want to ask questions verbally (optional - you can also type questions in chat)
  • Quiet space where you can listen for about an hour
Never used Zoom before? No problem! We'll send you a test link when you register so you can try it out beforehand. You can also call (626) 250-2070 if you need technical help.

How much time should I plan for this? Can I join late or leave early?

Plan for 40-50 minutes total, but you can join late or leave early if needed. We'll spend about 30 minutes explaining MS research updates then on Q&A, with some buffer time. The most important information comes first, so even if you can only stay for 30 minutes, you'll get the key points. Since we're recording, you can always catch what you missed.

Will you share my contact information or add me to marketing lists?

No. Your information stays with Modified by MS and SC3 Research Group only. We won't sell, share, or give your information to anyone else.
The only follow-up you'll get is the recording/summary email and occasional updates about future 'MS Research Roundup' sessions (which you can unsubscribe from anytime). If you want to learn more about clinical research opportunities, that's a separate conversation you'll initiate by calling SC3 directly.

Will this be too technical for someone without a medical background?

Absolutely not. Wayne specializes in translating complex research into plain English. We specifically avoid medical jargon and explain everything in terms that make sense to real people. If something isn't clear, just ask - that's what the Q&A portion is for. You don't need any medical background to understand and benefit from this session.

What if I can't attend live? Will I miss out?

You won't miss anything. We're recording the entire session and will email you the recording plus a written summary of key points within 24 hours. Many people actually prefer watching the recording because they can pause, rewind, and take notes at their own pace. Just register anyway - you'll get everything.

I'm not currently on any MS medication. Is this still relevant for me?

Yes, definitely. BTK inhibitors could become first-line treatments for newly diagnosed people or options for those who haven't found the right treatment yet. Understanding what's coming in the research pipeline helps you have more informed conversations with your neurologist about your treatment plan, regardless of where you are in your MS journey.

What Happens Next?

1

July 31: Join the live discussion. This session, we'll focus on BTKi.

2

August 16: Recording and summary sent to registered participants

3

Monthly: Future Research Roundup sessions announced

Join the Conversation About BTK Inhibitors

🔗 Just Join: [ZOOM LINK - Click Here to Join Aug 14, 6:00 PM CT]
No registration needed. Jump in and ask questions.

📧 Join + Get Follow-Up: Fill out the form below to get:

  • Event reminders (so you don't forget)
  • Recording link after the event
  • Key takeaways summary
  • Updates about future Research Real Talk sessions

Can't Make It Live? Register anyway - we'll send you the recording and key takeaways.
 
Questions Before the Event? Call SC3 Research Group at (626) 250-2070